PFE vs REPL

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Replimune (REPL) now faces a significantly heightened risk profile following the FDA's second Complete Response Letter (CRL) for RP1 in anti-PD-1-failed melanoma. This crucial setback invalidates the primary near-term catalyst and severely delays commercialization, pushing out any potential 10x growth within the 3-5 year timeframe. The market has reacted with a ~60% stock decline, widespread analy...